Spurred on by Moderna and Pfizer's success, a Belgian biotech has big ambitions for its self amplifying RNA vaccine play

With the first wave of mRNA-based Covid-19 vaccines providing proof of concept to the entire field, investors are seeing dollar signs for platform plays once considered moonshots. Now, a Belgian biotech is getting in on the craze with a hefty early fundraising haul for its own RNA platform.